List of Personalized Medicine Companies in Germany - 12

ALACRIS Theranostics GmbH is a Berlin-based systems medicine company founded in 2008, originating as a spin-off from the Max Planck Institute for Molecular Genetics. The company focuses on developing innovative solutions in healthcare, particularly in biomarker discovery, drug development, and precision medicine, with an emphasis on molecular oncology. The company offers comprehensive Next-Generation Sequencing (NGS) services that enhance precision medicine. By integrating advanced omics technologies with mechanistic computer modeling, ALACRIS develops biomarkers of drug response. Their services include high-dimensional data analytics and bioinformatics systems, tailored to meet medical needs in collaboration with clinicians. ALACRIS Theranostics is actively involved in partnerships with academia, biotechnology, and pharmaceutical companies, contributing to various research projects and applying their technologies in clinical settings. ALACRIS is committed to delivering data quickly while ensuring quality and confidentiality. Their interdisciplinary team combines expertise in sequencing technologies, advanced computing, and bioinformatics to provide effective healthcare solutions.

BIOTYPE is an innovative German solution provider for molecular precision diagnostics. We are committed to advancing precision medicine through our products & services for reliable analysis and interpretation of clinical biomarkers. BIOTYPE offers a strong portfolio in molecular cancer diagnostics for applications in hemato-oncology, liquid biopsy, and molecular profiling of solid tumors. The portfolio includes IVD assays for clinical diagnostics and RUO assays for translational and clinical research. In addition, BIOTYPE offers high-quality and IVD-compliant contract development and manufacturing services. Our proprietary MODAPLEX platform is a benchtop system for automated molecular profiling and multi-biomarker testing. MODAPLEX addresses the growing need to simplify and accelerate precision testing by reliably delivering actionable molecular information required for biomarker-guided care in precision medicine. The MODAPLEX consolidates multi-gene testing into one workflow with same-day results. BIOTYPE‘s quality management system is certified according to ISO 9001:2015 & ISO 13485:2016.

Epigenomics is a molecular diagnostics company focused on the development of blood-based DNA methylation tests for the early the detection of cancer. The Epi proColon test has recently become the first and only FDA approved blood test for colorectal cancer screening. Epi proColon, HCCBloodTest, and the Epi proLung tests are available in Europe as CE-marked IVDs. Industry partners, as well as the medical and life science communities, can access our expansive intellectual property portfolio. Epigenomics has been granted over 60 patents, in addition to many others that have been filed. These patents cover DNA methylation technologies and biomarkers, as well as our DNA methylation expertise through research products, biomarker services, IVD development collaborations, and licensing.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tubingen, Germany.

At Nostos Genomics, we partner with genetic testing labs to turn data into genomic insights and give more people with genetic diseases a fast and clear diagnosis. Over 300 million people live with a rare genetic disease and for most, the journey from the first symptoms to a diagnosis takes more than 5 years. Even after that, diagnoses are often incorrect, and many people end up not being diagnosed at all. Now, new technology is allowing millions to benefit from genetic testing for diagnosis, while at the same time targeted therapies for previously untreatable disorders are being developed. But the last step in genetic testing – interpreting mutations – remains laborious and costly. It can take a genetic testing lab weeks to interpret data from a single patient. Because of limited understanding of the consequences of mutations, the test results are often inconclusive and leave 70% of people undergoing a genetic test without diagnosis. Our CE-certified platform leverages a unique combination of machine learning and synthetic biology to characterize mutations at scale and automate the interpretation. By offering it to labs, we enable them to diagnose more people in a fraction of the time.

Omiqa is a contract research organisation, specialising in providing efficient bioinformatics solutions to support life scientist. Our expertise spans from conducting cutting-edge research and developing large-scale bioinformatic workflows to creating custom graphical web and desktop applications.

Siemens Healthineers is a leading medtech company with over 125 years of experience. We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Our portfolio, spanning in vitro and in vivo diagnostics to image-guided therapy and cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the greatest challenges in healthcare. We will continue to build on these strengths to help overcome the world's most threatening diseases, enable efficient operations, and expand access to care. We are a team of more than 71,000 Healthineers in over 70 countries passionately pushing the boundaries of what is possible in healthcare to help improve the lives of people around the world.

ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries. From research through product commercialization, we provide the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics as well as gene and cell therapy platforms. Our deep history of analytical leadership in protein-based therapeutics stems from the merger of Protagen Protein Services in Europe and BioAnalytix in the US. In 2021, GeneWerk’s unique capabilities in vector safety, integration site analysis, and bioinformatics were added to our portfolio, establishing ProtaGene. Our combined protein- and gene-based analytical platforms make it the leading analytic service provider across the biopharmaceutical and gene and cell therapy development spaces. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies worldwide.

SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies. SphingoTec GmbH was established in 2002 by Dr. Andreas Bergmann was one of the founders of B.R.A.H.M.S. AG. As former Chief Research Officer, he was responsible for the development of the "gold standard" sepsis biomarker Procalcitonin (B.R.A.H.M.S. PCT™).

The highly experienced research team founding the STRATIFYER Molecular Pathology GmbH has developed techniques to analyze routine tumor material for sophisticated molecular analysis. A specialized process has been developed that guarantees fast and reliable assessment of prognostic and predictive gene signatures in mid-throughput fashion. This technology has been exploited for multiple years to enable in-depth genomic research accompanying large clinical trials. First pathology labs have been powered by STRATIFYER Molecular Pathology GmbH to integrate RNA expression profiling tests in clinical routine. The molecular STRATIFYER test systems shall enable physicians to optimize anti-cancer treatment at patient's initial diagnosis according to individual differences of the tumors.

At Systasy, we accelerate the development of effective treatments by deepening our understanding of disease mechanisms. Our proprietary barcoding technology enhances every stage of the drug discovery pipeline, from target identification to patient stratification, utilizing hyper-multiplexed pathway screens and patient-derived models. Systasy's AI-supported platform excels in generating high-quality data for patient stratification and biomarker discovery. Additionally, our cutting-edge DNA barcoding technology empowers viral vector developers with unparalleled precision in understanding the biodistribution and cell-type-specific infectivity of multiple viral serotypes at once, fundamentally transforming healthcare.